Document and Entity Information Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus CONDENSED BALANCE SHEETS Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Accounts Receivable, Net, Current Accounts receivable, net of allowance of $114 and $107 as of September 30, 2014 and December 31, 2013 Inventory, Net Supplies inventory Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Deferred Tax Assets, Net of Valuation Allowance, Current Deferred tax asset Restricted Cash and Cash Equivalents, Current Restricted cash Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Net book value Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for acquired in-process research and development. Indefinite Lived In Process Research And Development In-process research and development Goodwill Restricted Cash and Cash Equivalents, Noncurrent Restricted cash as collateral for lease Restricted cash Long term deposit consisting of letter of credit serving as security for lease Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Outstanding obligations Accrued Liabilities, Current Accrued liabilities Accrued liabilities Deferred Revenue, Current Deferred Genzyme co-promotion fee Long-term Debt, Current Maturities Current portion of long-term debt Liabilities, Current Total current liabilities Long-term Debt, Excluding Current Maturities Long-term debt, net of current portion Deferred Tax Liabilities, Gross, Noncurrent Deferred tax liability Deferred Rent Credit, Noncurrent Deferred rent, net of current portion Deferred Revenue, Noncurrent Deferred Genzyme co-promotion fee, net of current portion Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note 5) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.001 par value; 5,000,000 shares authorized, 0 shares issued and outstanding as of September 30, 2014 and December 31, 2013, Common Stock, Value, Issued Common stock, $0.001 par value; 125,000,000 shares authorized, 22,490,488 and 21,143,313 shares issued and outstanding as of September 30, 2014 and December 31, 2013, respectively Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Allowance for Doubtful Accounts Receivable, Current Ending balance Beginning balance Accounts receivable, allowance (in dollars) Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Par value of shares of common stock (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Authorized shares of common stock Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Revenue, Net Revenue Operating Expenses [Abstract] Operating expenses: Cost of Revenue. Cost of revenue Research and Development Expense Research and development Selling and Marketing Expense Selling and marketing General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Interest Expense Interest expense Other Nonoperating Income (Expense) Other income (expense), net Net Income (Loss) Available to Common Stockholders, Basic Net loss Net loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Earnings Per Share, Basic and Diluted Net loss per common share, basic and diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Basic and Diluted Shares used to compute net loss per common share, basic and diluted (in shares) Shares used to compute net loss per common share, basic and diluted CONDENSED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Provision for Doubtful Accounts Bad debt expense Charged to expense Recognition of Deferred Revenue Genzyme co-promotion fee amortization Amortization of up-front co-promotion fee The aggregate amount of noncash, equity-based employee remuneration for non-bonus related compensation. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Share Based Compensation Non Bonus Related Stock-based compensation Amortization of Financing Costs and Discounts Amortization of debt discount and issuance costs Interest on debt balloon payment included in net income that resulted in no cash outflows in the period. Noncash Expense Interest On Debt Balloon Payment Interest on debt balloon payment Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss) Change in value of preferred stock liability Fair Value Adjustment of Warrants Change in value of preferred stock warrant liability Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Supplies inventory Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and current other assets Increase (Decrease) in Other Noncurrent Assets Other assets Increase (Decrease) in Accounts Payable Accounts payable The increase (decrease) during the reporting period in the amount of expenses incurred but not yet paid and deferred rent. Increase (Decrease) in Accrued Liabilities and Deferred Rent Accrued liabilities and deferred rent Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Investing activities Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Businesses, Net of Cash Acquired Cash remitted for acquisition, net of cash received Increase (Decrease) in Restricted Cash Change in restricted cash Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Financing activities Proceeds from Issuance of Long-term Debt Proceeds from the issuance of long-term debt, net of debt issuance costs Proceeds from Issuance of Redeemable Convertible Preferred Stock Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs The cash outflow for cost incurred directly with the issuance of an equity security in initial public offering. Payments of Stock Issuance Costs Initial Public Offering Commissions and issuance costs relating to the initial public offering Proceeds from Stock Options Exercised Proceeds from the exercise of common stock options Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Net Cash Provided by (Used in) Continuing Operations Net increase (decrease) in cash and cash equivalents Organization and Summary of Significant Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Organization and Summary of Significant Accounting Policies Net Loss Per Common Share Earnings Per Share [Text Block] Net Loss Per Common Share Business Combination Business Combination Disclosure [Text Block] Business Combination Accrued Liabilities. Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Liabilities Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Debt Debt Disclosure [Text Block] Debt Convertible Preferred Stock Warrant Disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants and Rights Note Disclosure [Text Block] Convertible Preferred Stock Warrant Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Stock Incentive Plans Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Incentive Plans Genzyme Co-promotion Agreement Collaborative Arrangement Disclosure [Text Block] Genzyme Co-promotion Agreement Thyroid Cytology Partners. Long-term Contracts or Programs Disclosure [Text Block] Thyroid Cytology Partners Income Taxes Income Tax Disclosure [Text Block] Income Taxes Subsequent Events. Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Disclosure of accounting policy for concentrations of credit risk and other risks and uncertainties. Concentrations of Credit and Other Risks and Uncertainties [Policy Text Block] Concentrations of Credit Risk and Other Risks and Uncertainties Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Restricted Cash Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Allowance for Doubtful Accounts Inventory Supplies, Policy [Policy Text Block] Supplies Inventory Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Internal Use Software, Policy [Policy Text Block] Internal-use Software Business Combinations Policy [Policy Text Block] Business Combinations Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Goodwill Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Intangible Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment of Long-lived Assets Compensation Related Costs, Policy [Policy Text Block] Bonus Accruals Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Cost of Sales, Policy [Policy Text Block] Cost of Revenue Research and Development Expense, Policy [Policy Text Block] Research and Development Income Tax, Policy [Policy Text Block] Income Taxes Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock-based Compensation Earnings Per Share, Policy [Policy Text Block] Net Loss per Common Share New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedule of the Company's significant third-party payers and their related revenue as a percentage of total revenue Allowance for Credit Losses on Financing Receivables [Table Text Block] Schedule of balance of allowance for doubtful accounts, including charges to bad debt expense and write-offs, net of recoveries Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of the calculation of basic and diluted net loss per common share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition Acquiree [Domain] Business Acquisition, Acquiree [Domain] Represents Allegro Diagnostics Corp., an acquiree of the entity. Allegro Diagnostics Corp [Member] Allegro Business Acquisition [Line Items] Tabular disclosure of components of acquisition consideration. Schedule of Components of Acquisition Consideration [Table Text Block] Schedule of acquisition consideration Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of fair value of assets acquired and liabilities assumed Business Acquisition, Pro Forma Information [Table Text Block] Schedule of pro forma financial information as if the Merger had occurred as of January1, 2013 Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued liabilities Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of future minimum lease payments under non-cancelable operating leases Schedule of Debt Schedule of net debt obligation Interest Income and Interest Expense Disclosure Schedule of interest expense on debt Tabular disclosure of number of common shares reserved for future issuance. Schedule of Common Stock Capital Shares Reserved for Future Issuance [Table Text Block] Schedule of reserved shares of common stock for issuance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Equity Award [Domain] An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, excluding options granted as bonus related compensation. Employee And Non Employee Stock Option Excluding Bonus Compensation [Member] Stock-based Compensation Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock incentive plans Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of activity under the Company's stock option plans Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Summary of outstanding and exercisable stock options Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Summary of stock based compensation expense related to stock options Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of assumptions used to calculate estimated grant date fair value of employee stock options using the Black-Scholes option-pricing valuation model Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Schedule of unamortized balance of the co-promotion fee reflected in the Company's condensed balance sheets Number of Operating Segments Number of operating segments Concentration Risk [Table] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Sales Revenue Net [Member] Revenue Accounts Receivable [Member] Accounts receivable Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Customer Concentration Risk [Member] Revenue concentration risk Credit Concentration Risk [Member] Gross receivables concentration risk Health Care Organization, Revenue Sources [Axis] Health Care Organization Revenue Sources [Domain] Health Care Organization, Revenue Sources [Domain] Represents information pertaining to Medicare, a significant third-party payer. Medicare [Member] Medicare Represents information pertaining to Aetna, a significant third-party payer. Aetna [Member] Aetna Represents information pertaining to United Healthcare, a significant third-party payer. United Healthcare [Member] United Healthcare Concentration Risk [Line Items] Concentrations of Credit Risk and Other Risks and Uncertainties Represents the number of major financial institutions, with which cash and cash equivalents are deposited by the entity. Number of Major Financial Institutions with which Cash and Cash Equivalents Deposited Number of major financial institutions with which the company's cash and cash equivalents are deposited Concentration Risk, Percentage Concentrations of credit risk (as a percent) The increase (decrease) in revenue during the current reporting period compared to the corresponding prior fiscal year period. Increase Decrease In Revenue Increase in revenue Restricted Cash and Investments [Abstract] Restricted Cash Allowance for Doubtful Accounts [Abstract] Allowance for Doubtful Accounts Allowance for Doubtful Accounts Receivable [Roll Forward] Activity of allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Write-offs Write-offs, net of recoveries Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property Plant And Equipment Type [Domain] Property, Plant and Equipment, Type [Domain] Software Development [Member] Capitalized software Range [Axis] Range [Member] Range [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Property, Plant and Equipment [Line Items] Property and Equipment and Internal-use Software Property, Plant and Equipment, Useful Life Estimated useful life Capitalized Computer Software, Net [Abstract] Property, Plant and Equipment, Gross Total cost Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation Capitalized Computer Software, Additions Capitalized costs Capitalized Computer Software, Amortization Amortization expense Asset Impairment Charges [Abstract] Long-lived Assets Impairment of Long-Lived Assets Held-for-use Impairments Employee-related Liabilities, Current [Abstract] Bonus Accruals Accrued Bonuses, Current Accrued liabilities associated with employee and executive bonus plans Earnings Per Share, Basic and Diluted [Abstract] Calculation of basic and diluted net loss per common share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Convertible Preferred Stock [Member] Shares of common stock issuable upon conversion of preferred stock An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, number of shares in the entity at a specified price, as defined in the agreement. Employee And Non Employee Stock Option [Member] Options Represents the security that gives the holder the right to purchase shares of common stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Common Stock Warrants [Member] Common Stock Warrants Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Total shares of common stock equivalents (in shares) Represents the number of shares of common stock of the acquired entity that each of the issued and outstanding shares of common stock of the subsidiary converted into under the agreement. Business Acquisition Number Of Shares Received For Each Subsidiary Share Number of Allegro shares received for each share of common stock issued and outstanding of a wholly-owned subsidiary of the Company Represents the number of shares of common stock of the reporting entity's subsidiary that the holders of the issued and outstanding preferred stock of the acquired entity had the right to receive upon cancellation under the agreement. Business Acquisition Right To Receive Upon Cancellation Of Preferred Stock Number Of Shares Conversion right, number of shares Represents the amount of cash that the holders of the issued and outstanding preferred stock of the acquired entity had the right to receive upon cancellation under the agreement. Business Acquisition Right To Receive Upon Cancellation Of Preferred Stock Cash Conversion right, cash The cash outflow as settlement for liabilities incurred by the acquirer as part of consideration transferred in a business combination. Outstanding indebtedness settled in cash Business Acquisition, Transaction Costs Acquisition-related costs Business Combination, Integration Related Costs Transaction bonuses and severance payments Business Combination, Consideration Transferred [Abstract] Acquisition consideration Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Stock Payments to Acquire Businesses, Gross Cash Business Combination, Consideration Transferred, Liabilities Incurred Payment of outstanding indebtedness Business Combination, Consideration Transferred Total acquisition consideration Business Acquisition, Share Price Closing price of Company's common stock Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract] Fair value of the assets acquired and liabilities assumed: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Prepaid expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Other current assets Amount of in-process research and development, having a projected indefinite period of benefit, acquired at the acquisition date. Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development In-process research and development Amount of accrued liabilities assumed at the acquisition date. Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Accrued Liabilities Accrued liabilities Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Total net assets acquired Fair Value Inputs, Discount Rate Discount rate (as a percent) Finite-Lived Intangible Asset, Useful Life Useful life Business Acquisition, Pro Forma Information [Abstract] Pro-Forma Financial Information Business Acquisition, Pro Forma Revenue Revenue Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Business Acquisition, Pro Forma Net Income (Loss) Net loss Employee-related Liabilities, Current Accrued compensation expenses Accrued Marketing Costs, Current Accrued Genzyme co-promotion fees Other Accrued Liabilities, Current Accrued other Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Fair Value Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Measurements Recurring [Member] Recurring Fair Value, Hierarchy [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Inputs Level1 [Member] Level I Asset Class [Axis] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Asset Class [Domain] Money Market Funds [Member] Money market funds Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value measurements Assets, Fair Value Disclosure Financial Assets Leases, Operating [Abstract] Operating Leases Security Deposit Cash security deposit included in other assets Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Future minimum lease payments under non-cancelable operating leases Operating Leases, Future Minimum Payments, Remainder of Fiscal Year October through December 31, 2014 Operating Leases, Future Minimum Payments, Due in Two Years 2015 Operating Leases, Future Minimum Payments, Due in Three Years 2016 Operating Leases, Future Minimum Payments, Due in Four Years 2017 Operating Leases, Future Minimum Payments, Due in Five Years 2018 Operating Leases, Future Minimum Payments Due Total minimum lease payments Operating Leases, Rent Expense, Net Facilities rent expense Purchase Obligation [Abstract] Volume Purchase Agreement Purchase Obligation Non-cancelable purchase obligations to contract manufacturers and suppliers Purchase Obligation, Due in Next Twelve Months Estimated amount payable in 2014 Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Longterm Debt Type [Domain] Long-term Debt, Type [Domain] Line Of Credit [Member] Loan and security agreement Represents term loan one of the reporting entity. Term Loan One [Member] Term loan Debt Instrument [Line Items] Debt Line of Credit Facility, Maximum Borrowing Capacity Maximum borrowing capacity Debt Instrument, Face Amount Amount drawn down Amount drawn down of term loan Debt Instrument, Unused Borrowing Capacity, Amount Amount not drawn Represents the number of installments for payment of the debt. Debt Instrument Number of Installments Number of installments Represents the period after the date of borrowing in which the debt is repayable under the agreement. Debt Instrument Period after which Debt is Repayable Period after which debt is repayable Debt Instrument, Interest Rate, Stated Percentage Interest rate (as a percent) Represents the percentage of prepayment penalties for prepayment within one year of the loan origination. Debt Instrument Penalty Percentage on Prepayment within One Year of Origination Prepayment penalties for prepayment within one year of the loan origination (as a percent) Represents the percentage of prepayment penalties for prepayment within two years of the loan origination. Debt Instrument Penalty Percentage on Prepayment within Two Years of Origination Prepayment penalties for prepayment within two years of the loan origination (as a percent) Represents the percentage of prepayment penalties for prepayment after two years of the loan origination. Debt Instrument Penalty Percentage on Prepayment after Two Years of Origination Prepayment penalties for prepayment after two years of the loan origination (as a percent) Long-term Debt, Gross Debt and unpaid accrued end-of-term payment Debt Instrument, Unamortized Discount Unamortized note discount Long-term Debt Net debt obligation Represents the amount of end of term payment of debt. Debt Instrument End of Term Payment Amount Amount of end of term payment Represents the end of term payment as a percentage of total outstanding principal balance of debt. Debt Instrument End of Term Payment as Percentage of Total Outstanding Principal End of term payment as a percentage of total outstanding principal balance Interest Expense, Debt, Excluding Amortization Nominal interest Amortization of Debt Discount (Premium) Amortization of debt discount Represents the amount of interest end of term payment of debt. Debt instrument end of term payment interest amount End of term payment interest Interest Expense, Debt Total Class of Warrant or Right [Table] Class of Warrant or Right [Axis] Class Of Warrant Or Right [Domain] Class of Warrant or Right [Domain] Represents the security that gives the holder the right to purchase shares of convertible preferred stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Convertible Preferred Stock Warrants [Member] Convertible Preferred Stock Warrants Class of Warrant or Right [Line Items] Convertible preferred stock warrant Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of shares of preferred stock that can be purchased by each warrant Original issue price of a single share of convertible preferred stock of a company. Convertible Preferred Stock Original Issue Price Issuance of convertible preferred stock, issue price (in dollars per share) Represents the number of securities for which warrants became exercisable. Class of Warrant or Right Number of Securities for which Warrants Became Exercisable Number of shares for which warrant became exercisable Number of shares of stock issued during the period as a result of the exercise of warrants. Stock Issued During Period Shares Warrants Exercised Issuance of common stock on exercise of warrant (in shares) Represents the number of votes for each share of stock. Voting Rights for Each Share of Stock Number of votes for each share of stock Dividends Payable Dividends declared Schedule of Stock by Class [Table] Class of Stock [Line Items] Common Stock Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Balance at the end of the period (in shares) Balance at beginning of the period (in shares) Options issued and outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Balance at the end of the period (in shares) Balance at the beginning of the period (in shares) Options available for grant under stock option plans (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Common stock warrants issued and outstanding (in shares) Common Stock, Capital Shares Reserved for Future Issuance Shares of common stock reserved for issuance Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Available for Grant [Roll Forward] Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Additional options authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Canceled (in shares) Canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Stock Options Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Options exercisable at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Options vested and expected to vest at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Balance at the end of the period (in dollars per share) Balance at beginning of the period (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Canceled (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Options exercisable at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Options vested and expected to vest at the end of the period (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Life [Abstract] Weighted Average Remaining Contractual Life Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Balance at the end of the period Balance at the beginning of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Contractual term Options exercisable at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Options vested and expected to vest at the end of the period Share Based Compensation Arrangement by Share Based Payment Award Options Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Balance at the end of the period (in dollars) Balance at the beginning of the period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Options exercisable at the end of the period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Options vested and expected to vest at the end of the period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Additional disclosures Share Price Estimated fair value common stock (in dollars per share) Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Exercise Price Range [Axis] Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Represents the exercise price of 0.08 dollars per share. Exercise Price Dollars0.08 [Member] $0.08 Represents the exercise price of 0.80 dollars per share. Exercise Price Dollars0.80 [Member] $0.80 Represents the exercise price of 2.36 dollars per share. Exercise Price Dollars2.36 [Member] $2.36 Represents the exercise price of 2.40 dollars per share. Exercise Price Dollars2.40 [Member] $2.40 Represents the exercise price of 2.68 dollars per share. Exercise Price Dollars2.68 [Member] $2.68 Represents the exercise price of 4.00 dollars per share. Exercise Price Dollars4.00 [Member] $4.00 Represents the exercise price of 6.04 dollars per share. Exercise Price Dollars6.04 [Member] $6.04 Represents the exercise price of 7.92 dollars per share. Exercise Price Dollars7.92 [Member] $7.92 ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis Exercise Price Dollars12.06 [Member] $12.06 ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByxercisePriceRangeAxis Exercise Price Dollars10.45 [Member] $10.45 Represents the range of exercise prices from 12.64 dollars to 18.24 dollars per share. Exercise Price Range From Dollars1264 To Dollars1824 [Member] $12.64 - 18.24 Represents the exercise price of 12.12 dollars per share. Exercise Price Dollars12.12 [Member] $12.12 Represents the range of exercise prices from 0.08 dollars to 18.24 dollars per share. Exercise Price Range From Dollars0.08 To Dollars18.24 [Member] $0.08-18.24 Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Outstanding and exercisable stock options Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Exercise price, low end of range (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Exercise price, high end of range (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Options Outstanding, Number (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Options Outstanding, Weighted-Average Remaining Contractual Life Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Options Vested and Exercisable, Number (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term Options Vested and Exercisable, Weighted-Average Remaining Contractual Life Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average fair value of stock options granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Weighted average fair value of stock options vested (in dollars per share) Employee Stock Option [Member] Employee stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Aggregate estimated grant date fair value of options to purchase common stock vested (in dollars) The weighted average grant-date fair value of options exercised during the reporting period. Share Based Compensation Arrangement by Share Based Payment Award Options Exercises in Period Weighted Average Grant Date Fair Value Weighted average fair value of stock options exercised (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Intrinsic value of stock options exercised (in dollars) Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost Of Sales [Member] Cost of revenue Research And Development Expense [Member] Research and development Selling And Marketing Expense [Member] Selling and marketing General And Administrative Expense [Member] General and administrative Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Stock-based compensation Allocated Share-based Compensation Expense Share-based compensation expense (in dollars) Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized compensation expense (in dollars) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Period over which unrecognized compensation expense expected to be recognized An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, excluding options granted as bonus compensation. Employee Stock Option Excluding Bonus Compensation [Member] Stock-based Compensation, employees and directors An arrangement whereby a non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Non Employee Stock Option [Member] Stock-based Compensation, non-employees Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Weighted-average volatility, low end of range (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Weighted-average volatility, high end of range (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Weighted-average expected term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, low end of range (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, high end of range (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield (as a percent) Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements And Nonarrangement Transactions [Member] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement Copromotion [Member] Co-promotion agreement Counterparty Name [Axis] Repurchase Agreement Counterparty Name [Domain] Counterparty Name [Domain] Represents information pertaining to Genzyme Corporation, a co-promoter. Genzyme Corporation [Member] Genzyme Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Accounts Payable [Member] Accounts payable Accrued Liabilities [Member] Accrued liabilities Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Genzyme Co-promotion Agreement Represents the number of countries outside United States in which marketing authorization is obtained under the agreement. Collaborative Arrangement Number of Countries Outside United States in which Marketing Authorization is Obtained Number of countries outside United States in which marketing authorization is obtained Increase (Decrease) in Deferred Revenue Co-promotion fee received from Genzyme Represents the additional payments that may be received under the agreement. Collaborative Arrangement Additional Payments That May Be Received Additional payments that may be received Represents the additional payments that may be received for each country outside of the United States in which the entity obtains marketing authorization and achieves a specified level of reimbursement under the agreement. Collaborative Arrangement Additional Payments that may be Received for Each Country Outside United States In which Entity Obtains Marketing Authorization and Achieves Specified Level of Reimbursement Additional payments that may be received for each country outside of the United States in which the company obtains marketing authorization and achieves a specified level of reimbursement Represents the number of countries outside United States for which additional payments may be received under the agreement. Collaborative Arrangement Number of Countries Outside United States for which Additional Payments May be Received Number of countries outside United States for which additional payments may be received Represents the co-promotion fees paid to co-promoter as a percentage of cash receipts under the agreement. Collaborative Arrangement Co-promotion fees percentage of cash receipts Co-promotion fees as a percentage of cash receipts Represents the co-promotion fees paid to co-promoter as a percentage of cash receipts for the remaining periods under the agreement. Collaborative Arrangement Co-promotion fees percentage of cash receipts remaining periods Co-promotion fees as a percentage of cash receipts for remaining periods Co-promotion fees as a percentage of cash receipts Represents the maximum amount to be spent by co-promoter for qualifying clinical development activities in countries that require additional testing for approval under the agreement. Collaborative Arrangement Maximum Amount to be Spent by Co Promoter for Qualifying Clinical Development Activities in Countries that Require Additional Testing for Approval Maximum amount to be spent by co-promoter for qualifying clinical development activities in countries that require additional testing Represents the co-promotion fees to be paid to co-promoter as a percentage of cash receipts beginning in the fiscal year following the current fiscal year under the amended agreement. Collaborative Arrangement Co Promotion Fees Percentage Of Cash Receipts Next Fiscal Year Co-promotion fees as a percentage of cash receipts beginning January 1, 2015 Represents the amortization period of co-promotion fee. Collaborative Arrangement Co Promotion Fee Amortization Period Amortization period of co-promotion fee Represents the amount of co-promotion expenses incurred under the agreement. Collaborative Arrangement Co Promotion Expenses Co-promotion expenses Represents the amount of outstanding obligation under the agreement. Collaborative Arrangement Outstanding Obligation Outstanding obligation to Genzyme Deferred Revenue [Abstract] Unamortized balance of the co-promotion fee Deferred Revenue Total Schedule of Variable Interest Entities [Table] Variable Interest Entities [Axis] Classification Of Variable Interest Entity [Domain] Variable Interest Entity, Classification [Domain] Variable Interest Entity Not Primary Beneficiary [Member] Thyroid Cytology Partners Variable Interest Entity [Line Items] Thyroid Cytology Partners Testing and evaluation service costs directly related to generating revenues. Testing and Evaluation Services Expense Expenses for cytopathology testing and evaluation services Amount of reimbursement from third party for rent and related operating expenses for shared space included in other income in the income statement. Other Income Rent Reimbursement Reimbursed rent expense included in other income Unrecognized Tax Benefits Unrecognized tax benefit Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized tax benefits, which if recognized, would affect the effective tax rate Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Events Subsequent Event [Line Items] Subsequent Events Finite-Lived Intangible Assets by Major Class [Axis] Finite Lived Intangible Assets Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] In Process Research And Development [Member] IPR&D Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Domain] Nonrecurring Adjustment [Domain] Category of transaction bonuses, other payment to employees and acquisition-related costs allocated to (included in) reported pro forma earnings (supplemental pro forma information). Transaction Bonuses Other Payments To Employees And Acquisition Related Expenses [Member] Transaction bonus and other payments to employees and acquisition related costs Interest expense related to indebtedness of acquired entity allocated to (included in) reported pro forma earnings (supplemental pro forma information). Interest Expense Related To Indebtedness Of Acquired Entity [Member] Interest expense related to indebtedness of acquired entity